Eric Anton Hughes MD, PhD
Immunology and Microbiology, Infectious Disease
East Hanover, New Jersey, United States of America
Connect with the speaker?
Eric Hughes joined Novartis in 2015 and leads the Immunology and Dermatology (I&D) Unit. He and his team are responsible for the clinical development and regulatory approvals of Cosentyx and a number of innovative treatments within the Unit.
Prior to joining Novartis, Eric worked for Bristol-Myers Squibb (BMS) Company for five years, most recently as Vice President and Head of Specialty Discovery Medicine, Exploratory Clinical and Translational Research. While at BMS, Eric led the simultaneous approval of two compounds, Daklinza (daclatasvir) and Sunvepra® (asunaprevir), and had extensive experience working with regulatory agencies around the world.
Prior to joining Novartis, Eric worked for Bristol-Myers Squibb (BMS) Company for five years, most recently as Vice President and Head of Specialty Discovery Medicine, Exploratory Clinical and Translational Research. While at BMS, Eric led the simultaneous approval of two compounds, Daklinza (daclatasvir) and Sunvepra® (asunaprevir), and had extensive experience working with regulatory agencies around the world.
EVENTS & ACTIVITIES (Speaking, Spoken, and Authored)
Quick Links
- 50 Division Street, Suite 501,
- Somerville, NJ 08876
- support@emedevents.com